Insider Selling: Zai Lab (NASDAQ:ZLAB) Insider Sells $36,626.58 in Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) insider Joshua Smiley sold 1,966 shares of the stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $18.63, for a total transaction of $36,626.58. Following the completion of the sale, the insider owned 91,026 shares of the company’s stock, valued at $1,695,814.38. This trade represents a 2.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Zai Lab Trading Down 1.0%

ZLAB opened at $18.83 on Thursday. Zai Lab Limited Unsponsored ADR has a twelve month low of $15.96 and a twelve month high of $44.34. The firm has a market capitalization of $2.12 billion, a PE ratio of -11.70 and a beta of 0.85. The firm’s 50-day moving average price is $18.69 and its 200 day moving average price is $22.84.

Zai Lab (NASDAQ:ZLAB) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.02). Zai Lab had a negative net margin of 38.15% and a negative return on equity of 22.81%. The business had revenue of $127.60 million during the quarter, compared to analyst estimates of $122.67 million. As a group, analysts predict that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current fiscal year.

Institutional Trading of Zai Lab

An institutional investor recently raised its position in Zai Lab stock. SG Americas Securities LLC boosted its holdings in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 10,396 shares of the company’s stock after acquiring an additional 642 shares during the period. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 41.65% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on ZLAB shares. JPMorgan Chase & Co. cut their price target on Zai Lab from $39.00 to $32.00 and set an “overweight” rating for the company in a report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Zai Lab in a report on Wednesday, January 21st. Zacks Research downgraded Zai Lab from a “hold” rating to a “strong sell” rating in a research note on Friday, January 23rd. Cantor Fitzgerald reduced their price target on Zai Lab from $55.00 to $37.00 and set an “overweight” rating on the stock in a report on Friday, February 27th. Finally, UBS Group assumed coverage on shares of Zai Lab in a research report on Wednesday, January 7th. They set a “buy” rating and a $35.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Zai Lab currently has an average rating of “Moderate Buy” and a consensus price target of $50.00.

About Zai Lab

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.